27mon MSN
The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.
A small but significant new study showed low doses of Ozempic helped people to drink less. Scientists are starting to ...
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results